VRDN FY 2020 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-76.5% YoY

Gross Profit

-$27M-2595.6% margin

Operating Income

-$110M-10512.4% margin

Net Income

-$111M-10544.3% margin

EPS (Diluted)

$-31.20

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$131M

Total Liabilities

$11M

Stockholders' Equity

$120M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-76.5%
Gross Profit	-$27M	$4M	-710.9%
Operating Income	-$110M	-$42M	-162.9%
Net Income	-$111M	-$42M	-164.4%